Medpace (NASDAQ:MEDP) CEO Sells 11,366 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 11,366 shares of Medpace stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $601.53, for a total transaction of $6,836,989.98. Following the completion of the transaction, the chief executive officer directly owned 604,436 shares in the company, valued at approximately $363,586,387.08. The trade was a 1.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Medpace Price Performance

Shares of Medpace stock traded down $3.45 on Friday, hitting $578.50. The company had a trading volume of 215,633 shares, compared to its average volume of 352,984. The stock has a 50-day moving average of $533.75 and a 200-day moving average of $491.74. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The firm has a market capitalization of $16.15 billion, a P/E ratio of 33.91, a P/E/G ratio of 2.66 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period last year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on MEDP shares. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and boosted their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. TD Cowen lifted their target price on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Truist Financial upped their price target on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $584.18.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MEDP. BlackRock Inc. bought a new position in shares of Medpace in the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC raised its holdings in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after acquiring an additional 324,293 shares in the last quarter. Wasatch Advisors LP raised its holdings in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares in the last quarter. Geode Capital Management LLC boosted its position in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.